Zurich Cantonal Bank
SYRE icon

Zurich Cantonal Bank’s Spyre Therapeutics SYRE Stock Holding History

Zurich Cantonal Bank’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Buy
26,143
+12,188
+87% +$889K ﹤0.01% 1050
2026
Q1 		$704K Buy
13,955
+2,791
+25% +$105K ﹤0.01% 1630
2025
Q4 		$366K Buy
11,164
+290
+3% +$7.58K ﹤0.01% 1952
2025
Q3 		$182K Sell
10,874
-1,999
-16% -$32.6K ﹤0.01% 2235
2025
Q2 		$193K Buy
+12,873
New +$190K ﹤0.01% 2154

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Zurich Cantonal Bank's SYRE Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Spyre Therapeutics (SYRE) stake by 87% in Q2 2026, buying an estimated $889K and bringing the position to 26,143 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

Zurich Cantonal Bank first reported a position in SYRE in Q2 2025 and has held it in 5 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Zurich Cantonal Bank held 26,143 shares of Spyre Therapeutics worth $2.32M as of Q2 2026.
  • Zurich Cantonal Bank bought 12,188 Spyre Therapeutics shares in Q2 2026, an estimated $889K.
  • Spyre Therapeutics made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #1050 holding.
  • Zurich Cantonal Bank first reported a position in Spyre Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.